ADAM12 and neoplasm: Using a xenograft model, we found that knocking out CAR10 obviously inhibited the tumor growth and yielded significantly smaller tumors after 5 weeks, as compared with A549 CRISPR-CTR cells (Fig. 3a, b and Supplementary Figure 3E).